Pilot study to measure exposure to atazanavir, as a component of pharmacokinetic parameters and adherence measured with MEMS [Micro-Electro-Mechanical-Systems] in naive HIV-infected patients treated once daily with atazanavir combined to ritonavir and to tenofovir/emtricitabine. ANRS 134 Cophar 3.

Trial Profile

Pilot study to measure exposure to atazanavir, as a component of pharmacokinetic parameters and adherence measured with MEMS [Micro-Electro-Mechanical-Systems] in naive HIV-infected patients treated once daily with atazanavir combined to ritonavir and to tenofovir/emtricitabine. ANRS 134 Cophar 3.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 May 2014

At a glance

  • Drugs Atazanavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Ritonavir (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Acronyms COPHAR-3
  • Most Recent Events

    • 08 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Oct 2008 Actual patient number (35) added as reported by ClinicalTrials.gov.
    • 23 Oct 2008 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top